An interventional study of Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation in Atrial Fibrillation, sponsored by Biosense Webster, Inc.. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Biosense Webster, Inc. (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Atrial Fibrillation by Johnson & Johnson — 7 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Johnson & Johnson.
Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 33rd largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2024, is one of 34 with no phase, and was the 60th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →7 of the 71 studies in Atrial Fibrillation by Johnson & Johnson are open now, in 5 countries. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in China
Ages 18–80
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18–80
Biosense Webster, Inc. · Sites in United States
Ages 18–80
Biosense Webster, Inc. · Sites in United States
Ages 18–80
Biosense Webster, Inc. · Sites in United States
Ages 22+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is close to the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 149 across the 58 interventional studies, 426 across the 13 observational. Of the 57 that completed or were terminated, 40 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Biosense Webster, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Biosense Webster, Inc. is the lead sponsor of 64 studies on the registry; 8 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 25 (96%) have results posted.
6 of the studies in Atrial Fibrillation by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
| NCT03963349Biosense Webster, Inc.THERMOCOOL SMARTTOUCH®SF Catheters With Ablation Index Study | 2026-12-31 |
| NCT07116525Biosense Webster, Inc.A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter | 2027-02-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.
Inclusion Criteria::
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.
Device: Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation
THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
Number of Participants With Primary Adverse Events (PAEs)
An adverse event (AE) was any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including abnormal laboratory finding, in participants or users in context of clinical investigation, whether or not related to device/procedure. PAEs included the following adverse events: Device or procedure related death within 30 days of ablation procedure, esophageal perforating complications (atrio-esophageal fistula \[up to 90 days post ablation procedure\], esophago-pericardial fistula), myocardial infarction, cardiac tamponade/perforation up to 30 days post ablation, thromboembolism, stroke/cerebrovascular accident (CVA), transient ischemic attack (TIA), phrenic nerve paralysis, pulmonary vein stenosis (occurring anytime during 12 month follow-up period considered a PAE), major vascular access complication/bleeding, pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis.
Time frame: Up to 12 Months post ablation procedure on Day 0
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes
Percentage of participants with freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (AF, AT or AFL) episodes based on electrocardiographic data and from all failure modes were reported. Atrial tachyarrhythmia (AF/AT/AFL of unknown origin) episodes were based on electrocardiographic data \[12-lead electrocardiogram(ECG) or greater than or equal to(\>=) 30 seconds on ECG or sponsor provided transtelephonic monitor (TTM) or Holter device\] during effectiveness evaluation period (Day 91 to Day 365) and any of following failure modes: acute procedural, repeat ablation, non-study device, anti-arrhythmic drug (AAD), continuous AF/AT/AFL of unknown origin, and any direct current cardioversion procedure during evaluation period for documented atrial tachyarrhythmia (AF/AT/AFL of unknown origin). AFL of unknown origin was defined as all AFL except those cavotricuspid isthmus dependent AFL as confirmed by 12-Lead ECG and entrainment maneuvers in an electrophysiology (EP) study.
Time frame: From Day 91 up to Day 365 post ablation procedure on Day 0
Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12
Change from baseline in AFEQT total score at Month 12 was reported. AFEQT questionnaire was used to assess the quality-of-life post ablation procedure. The AFEQT questionnaire included 20 questions on a 7-point Likert scale. Questions 1-18 evaluated health-related quality of life (HRQoL), including AF-related symptoms (Questions 1-4), daily activities (Questions 5-12), and treatment concerns (Questions 13-18), while Questions 19-20 assessed participant satisfaction with treatment. The first 18 questions were used to calculate the overall AFEQT scores. Scores are transformed to a scale ranging from 0 to 100, where a score of 0 indicated complete disability and a score of 100 indicated no disability. Higher scores indicated improvement. The formula to calculate these scores is as follows: 100 minus(\[sum of severity for all questions answered minus number of questions answered\]\*100 divided by total number questions answered\*6).
Time frame: Baseline, Month 12
| Milestone | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| Started | 136 |
| All treated (at) analysis set | 133 |
| Completed | 127 |
| Not completed | 9 |
| Withdrew: Enrolled but not treated | 3 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 2 |
An adverse event (AE) was any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including abnormal laboratory finding, in participants or users in context of clinical investigation, whether or not related to device/procedure. PAEs included the following adverse events: Device or procedure related death within 30 days of ablation procedure, esophageal perforating complications (atrio-esophageal fistula \[up to 90 days post ablation procedure\], esophago-pericardial fistula), myocardial infarction, cardiac tamponade/perforation up to 30 days post ablation, thromboembolism, stroke/cerebrovascular accident (CVA), transient ischemic attack (TIA), phrenic nerve paralysis, pulmonary vein stenosis (occurring anytime during 12 month follow-up period considered a PAE), major vascular access complication/bleeding, pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis.
| Participants | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| Number of Participants With Primary Adverse Events (PAEs) | 6 |
Percentage of participants with freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (AF, AT or AFL) episodes based on electrocardiographic data and from all failure modes were reported. Atrial tachyarrhythmia (AF/AT/AFL of unknown origin) episodes were based on electrocardiographic data \[12-lead electrocardiogram(ECG) or greater than or equal to(\>=) 30 seconds on ECG or sponsor provided transtelephonic monitor (TTM) or Holter device\] during effectiveness evaluation period (Day 91 to Day 365) and any of following failure modes: acute procedural, repeat ablation, non-study device, anti-arrhythmic drug (AAD), continuous AF/AT/AFL of unknown origin, and any direct current cardioversion procedure during evaluation period for documented atrial tachyarrhythmia (AF/AT/AFL of unknown origin). AFL of unknown origin was defined as all AFL except those cavotricuspid isthmus dependent AFL as confirmed by 12-Lead ECG and entrainment maneuvers in an electrophysiology (EP) study.
| Percentage of participants | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes | 59.6 (50.5 to 68.6) |
Change from baseline in AFEQT total score at Month 12 was reported. AFEQT questionnaire was used to assess the quality-of-life post ablation procedure. The AFEQT questionnaire included 20 questions on a 7-point Likert scale. Questions 1-18 evaluated health-related quality of life (HRQoL), including AF-related symptoms (Questions 1-4), daily activities (Questions 5-12), and treatment concerns (Questions 13-18), while Questions 19-20 assessed participant satisfaction with treatment. The first 18 questions were used to calculate the overall AFEQT scores. Scores are transformed to a scale ranging from 0 to 100, where a score of 0 indicated complete disability and a score of 100 indicated no disability. Higher scores indicated improvement. The formula to calculate these scores is as follows: 100 minus(\[sum of severity for all questions answered minus number of questions answered\]\*100 divided by total number questions answered\*6).
| Score on scale | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12 | 31.59 ± 22.216 |
Collected over All cause mortality: From screening (90 days prior to Day 0) up to the end of the study (12 months); Serious and other adverse events: From Day 0 (post-procedure) up to the end of the study (12 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation | 1/136 (0.7%) | 17/133 (12.8%) | 57/133 (42.9%) |
| Event | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| BradycardiaCardiac disorders | 3/133 |
| PericarditisCardiac disorders | 3/133 |
| Atrial flutterCardiac disorders | 2/133 |
| Pericardial effusionCardiac disorders | 2/133 |
| PresyncopeNervous system disorders | 2/133 |
| HypotensionVascular disorders | 2/133 |
| Non-cardiac chest painGeneral disorders | 2/133 |
| Atrioventricular blockCardiac disorders | 1/133 |
| Atrioventricular block second degreeCardiac disorders | 1/133 |
| Myocardial infarctionCardiac disorders | 1/133 |
| Event | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| EcchymosisSkin and subcutaneous tissue disorders | 9/133 |
| Atrial flutterCardiac disorders | 8/133 |
| PericarditisCardiac disorders | 4/133 |
| DiarrhoeaGastrointestinal disorders | 4/133 |
| NauseaGastrointestinal disorders | 4/133 |
| Atrial tachycardiaCardiac disorders | 3/133 |
| Non-cardiac chest painGeneral disorders | 3/133 |
| DizzinessNervous system disorders | 3/133 |
| Obstructive sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 3/133 |
| Chest painGeneral disorders | 2/133 |
Safety analysis set included all enrolled participants who had insertion of the study catheter, regardless of energy delivery.
| Age, Continuous(Years) | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| Mean | 63.3 ± 9.89 |
| Sex: Female, Male(Participants) | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| Female | 57 |
| Male | 76 |
| Ethnicity (NIH/OMB)(Participants) | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 116 |
| Unknown or Not Reported | 15 |
| Race (NIH/OMB)(Participants) | Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 8 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 116 |
| More than one race | 0 |
| Unknown or Not Reported | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Feb 2024 to primary completion in Oct 2025, 20 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 20 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.